IL263504A - Taxoid nanoemulsion medicinal preparations, and methods for their targeted use in cancer cells and cancer stem cells - Google Patents

Taxoid nanoemulsion medicinal preparations, and methods for their targeted use in cancer cells and cancer stem cells

Info

Publication number
IL263504A
IL263504A IL263504A IL26350418A IL263504A IL 263504 A IL263504 A IL 263504A IL 263504 A IL263504 A IL 263504A IL 26350418 A IL26350418 A IL 26350418A IL 263504 A IL263504 A IL 263504A
Authority
IL
Israel
Prior art keywords
cells
methods
stem cells
cancer
nanoemulsion compositions
Prior art date
Application number
IL263504A
Other languages
English (en)
Hebrew (he)
Inventor
E Egan James
Ojima Iwao
M Amiji Mansoor
Ivanovna BOTCHKINA Galina
Original Assignee
Targagenix Inc
Univ New York State Res Found
Univ Northeastern
E Egan James
Ojima Iwao
M Amiji Mansoor
Ivanovna BOTCHKINA Galina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc, Univ New York State Res Found, Univ Northeastern, E Egan James, Ojima Iwao, M Amiji Mansoor, Ivanovna BOTCHKINA Galina filed Critical Targagenix Inc
Publication of IL263504A publication Critical patent/IL263504A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL263504A 2016-06-07 2018-12-04 Taxoid nanoemulsion medicinal preparations, and methods for their targeted use in cancer cells and cancer stem cells IL263504A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346755P 2016-06-07 2016-06-07
PCT/US2017/036330 WO2017214260A1 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Publications (1)

Publication Number Publication Date
IL263504A true IL263504A (en) 2019-01-31

Family

ID=60578981

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263504A IL263504A (en) 2016-06-07 2018-12-04 Taxoid nanoemulsion medicinal preparations, and methods for their targeted use in cancer cells and cancer stem cells

Country Status (9)

Country Link
US (3) US10206875B2 (cg-RX-API-DMAC7.html)
EP (1) EP3463299A4 (cg-RX-API-DMAC7.html)
JP (1) JP7518604B2 (cg-RX-API-DMAC7.html)
CN (2) CN116019768A (cg-RX-API-DMAC7.html)
AU (1) AU2017277497B2 (cg-RX-API-DMAC7.html)
CA (1) CA3026412A1 (cg-RX-API-DMAC7.html)
IL (1) IL263504A (cg-RX-API-DMAC7.html)
MX (1) MX2018015112A (cg-RX-API-DMAC7.html)
WO (1) WO2017214260A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116019768A (zh) * 2016-06-07 2023-04-28 塔佳吉尼克斯公司 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合
US20220226480A1 (en) * 2019-03-22 2022-07-21 Integrated Nanotherapeutics Inc. Lipid conjugate prepared from scaffold moiety
AU2020370372A1 (en) * 2019-10-25 2022-05-12 Amgen Inc. Compositions and methods for minimizing protein loss at low protein concentrations
EP4054550A4 (en) * 2019-11-05 2024-01-17 Luminus Biosciences Inc. NANOPARTICLES WITH PRODRUGS STABILIZED BY ALBUMIN FOR THE TREATMENT OF CANCER AND OTHER DISEASES
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114317398B (zh) * 2020-09-27 2024-03-01 中国科学院分子细胞科学卓越创新中心 Gli1和EpCAM基因共同标记的肝祖细胞群及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
CA2544128A1 (en) * 2003-10-30 2005-05-12 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
AU2009280803B2 (en) * 2008-07-23 2013-10-31 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water Docetaxel nanoemulsion
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
US20140105829A1 (en) * 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same
KR102397569B1 (ko) * 2014-06-19 2022-05-12 솔루랄 파마 에이피에스 친유성 화합물의 고형 경구 투여 형태
US10736842B2 (en) * 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
CN116019768A (zh) * 2016-06-07 2023-04-28 塔佳吉尼克斯公司 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合

Also Published As

Publication number Publication date
AU2017277497A1 (en) 2018-12-20
CA3026412A1 (en) 2017-12-14
USRE50096E1 (en) 2024-08-27
EP3463299A4 (en) 2020-01-15
NZ748915A (en) 2024-09-27
JP7518604B2 (ja) 2024-07-18
EP3463299A1 (en) 2019-04-10
US20250009658A1 (en) 2025-01-09
AU2017277497B2 (en) 2023-05-04
JP2019523226A (ja) 2019-08-22
US20180028442A1 (en) 2018-02-01
MX2018015112A (es) 2019-09-09
WO2017214260A1 (en) 2017-12-14
CN109562065A (zh) 2019-04-02
US10206875B2 (en) 2019-02-19
CN116019768A (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
IL269444B (en) New modified indazoles, methods for their production, pharmaceutical preparations containing the new modified indazoles, and the use of the new modified indazoles in the production of drugs
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
EP3258941A4 (en) Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
IL263341A (en) Stem cell material, compounds and methods of use
IL257274B (en) Compositions and methods for treating cancers associated with etbr activation
IL290114A (en) Pharmaceutical preparations, their preparation and uses
IL261623A (en) Stem cells expressing mesenchymal and neuronal markers, compositions containing them and methods for their preparation
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
PT3223796T (pt) Composições farmacêuticas, preparação e suas utilizações
EP3111951A4 (en) Anticancer functional peptide for inhibiting proliferation of cancer stem cell, and use thereof
GB201613078D0 (en) Stem cells and cancer
EP3463299A4 (en) NANO EMULSION COMPOSITIONS OF TAXOID ACTIVE SUBSTANCES AND METHOD FOR USE THEREOF AGAINST CANCER CELLS AND CANCER STEM CELLS
LT3229843T (lt) Farmacinė kompozicija, jos paruošimo būdas ir naudojimas
EP3151826A4 (en) Omega-3 compositions, dosage forms, and methods of use
PT3503885T (pt) Composição farmacêutica e métodos de utilização
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
IL258242B (en) Compositions and methods for inhibiting cancer stem cells
HK40006913A (en) Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
GB201520226D0 (en) Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methodsof use thereof.
HK40003869A (en) Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
GB201415969D0 (en) Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methods of use thereof
HK1258652A1 (en) Methods and compositions for the treatment of head and neck cancer
HK1234671A1 (en) Omega-3 compositions, dosage forms, and methods of use